Literature DB >> 33594254

Ipilimumab can be safely omitted.

Peter Sidaway1.   

Abstract

Entities:  

Year:  2021        PMID： 33594254     DOI： 10.1038/s41571-021-00483-3

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.

Authors:  Michael Boyer; Mehmet A N Şendur; Delvys Rodríguez-Abreu; Keunchil Park; Dae Ho Lee; Irfan Çiçin; Perran Fulden Yumuk; Francisco J Orlandi; Ticiana A Leal; Olivier Molinier; Nopadol Soparattanapaisarn; Adrian Langleben; Raffaele Califano; Balazs Medgyasszay; Te-Chun Hsia; Gregory A Otterson; Lu Xu; Bilal Piperdi; Ayman Samkari; Martin Reck
Journal:  J Clin Oncol       Date:  2021-01-29       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.